Analyst Ratings For Destiny Pharma PLC (LON:DEST)
Today, FinnCap reiterated its Corporate rating on Destiny Pharma PLC (LON:DEST).
There are 0 Strong Buy Ratings, no Sell Ratings, no Hold Ratings, no Buy Ratings on the stock.
The current consensus rating on Destiny Pharma PLC (LON:DEST) is N/A with a consensus target price of GBX 250 per share, a potential .
Some recent analyst ratings include
- 9/26/2018-Destiny Pharma PLC (LON:DEST) had its Corporate rating reiterated by FinnCap
About Destiny Pharma PLC (LON:DEST)
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections. The company has collaboration agreement with China Medical System Holdings Limited. The company was incorporated in 1996 and is headquartered in Brighton, the United Kingdom.
Recent Trading Activity for Destiny Pharma PLC (LON:DEST)
Shares of Destiny Pharma PLC closed the previous trading session at 89,75 +0,75 0,84 % with 4.19 shares trading hands.
